Federal News

Displaying results 1-10 (of 57)
 |<  < 1 2 3 4 5 6  >  >| 

AMA House of Delegates Policy Update

At the AMA’s Annual House of Delegate Meeting, hundreds of medical professionals gathered to discuss and address a wide range of healthcare issues, including the opioid crisis, physician burnout, regulating physician assistants and advanced practice registered nurses, and of course, healthcare reform and drug pricing.

READ MORE

States move to enforce FDA’s Biosimilar Interchangeability Guidelines from the Ground Up

The Food and Drug Administration’s guidelines for biosimilar interchangeability, released in January 2017, have come under renewed focus with concerns about patients being switched onto biosimilars by insurers without consultation with their physicians.

READ MORE

Senate HELP Committee Wades into Drug Prices Debate

Despite intractable differences between the parties on healthcare policy, the Senate’s Health, Education, Labor, and Pensions Committee (HELP) convened a hearing this week to frame future efforts in combating high drug prices.

READ MORE

Leading Health Organizations Announce Launch of Alliance for Transparent & Affordable Prescriptions

Health leaders today announced the launch of the Alliance for Transparent & Affordable Prescriptions (ATAP), a coalition of provider and patient groups concerned about the practices of pharmacy benefit managers (PBMs) driving up drug costs.

READ MORE

Formulary Changes Hurt the Patients Most

Rheumatologists are at the forefront of innovative treatments for patients with complex autoimmune diseases such as rheumatoid arthritis.

READ MORE

New Legislation Could Shine a Light on the Elusive World of Prescription Drug Pricing

Ever-increasing drug prices have recently been at the forefront of the healthcare debate in America, and a new bill introduced in Congress last week may be the important first step in shedding light on the intermediaries who play a huge yet largely unnoticed role in drug pricing: Pharmacy Benefit Managers (PBMs).

READ MORE

CSRO Submits Interchangeability Comments to FDA

As patient and physician advocates, we have been deeply involved in the debate surrounding implementation of the Biologics Price Competition and Innovation Act (BPCIA).

READ MORE

Advocating for Your Patients and Your Practice

Government regulations are constantly felt within the healthcare industry, and more specifically within rheumatology, so it is important to remember that advocating on behalf of one’s own practice is proactive towards the needs of the physician, and ultimately the patient.

READ MORE

FDA Finalizes Standard for Non-Proprietary Naming of Biologics and Biosimilars

The FDA announced the release of the final guidance on the “Nonproprietary Naming of Biological Products.”

READ MORE

MACs Continue Efforts to Downcode Cimzia and Other Biologics

Concern among the rheumatology community continues to mount over growing efforts by various Medicare Administrative Contractors (MACs) to downcode the administration coding for certain biologics from complex to simple.

READ MORE

Displaying results 1-10 (of 57)
 |<  < 1 2 3 4 5 6  >  >|